Moderna shares surged 8% to $204.60 as investors anticipate the full Phase 3 melanoma vaccine trial data to be presented at the European Society for Medical Oncology (ESMO) congress in Madrid. The vaccine, developed with Merck, showed promising results in reducing cancer recurrence when combined with Keytruda, but the complete dataset has not yet been publicly released. This data release is crucial as it could validate Moderna's potential new revenue stream beyond infectious diseases. BioNTech and Pfizer showed smaller stock movements, reflecting their earlier-stage cancer vaccine programs compared to Moderna's advanced trial.
Moderna shares are up 7.97% at $205.16 on Pluang, closely matching the article's noted 8% rise. BioNTech also gained 1.28%, while Pfizer slipped 1.08%. These movements reflect investor focus on the melanoma vaccine data ahead of the ESMO congress. All prices and changes are as of Oct 06, 2026 02:01 WIB.
In September, technology stocks led the S&P 500's best performers, with 13 of the top 20 winners coming from the sector. Everpure topped the list with a 40.7% gain, followed by Moderna, Intel, and Bloom Energy, each rising over 30%. On the downside, ...
Nike reported a 4% decline in Q1 sales, driven by a 22% drop in China revenue, impacting its overall performance and leading to a 9% premarket share decline. Moderna will replace Warner Bros Discovery in the Nasdaq-100, reflecting its strong market p...
Moderna shares climbed 3% even after Citigroup downgraded the stock to Sell, citing high valuation following a 222% rise since positive melanoma vaccine trial results. The market seems optimistic about Moderna's personalized cancer vaccine pipeline, ...
